SG11201910096RA - Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use - Google Patents

Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Info

Publication number
SG11201910096RA
SG11201910096RA SG11201910096RA SG11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA SG 11201910096R A SG11201910096R A SG 11201910096RA
Authority
SG
Singapore
Prior art keywords
international
boost
adimab
lebanon
lucent
Prior art date
Application number
Inventor
Laura M Walker
Robert Pejchal
Eric Krauland
Maximiliano Vasquez
Monica Wai Ling Leung
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of SG11201910096RA publication Critical patent/SG11201910096RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Days 28 Days 42 Days 7 Days I Immunization Strategy Primary Immunization 1 st Boost 2 nd Boost 3 rd Boost Sac Primary Immunization: 1.0x10 6 Purified Human T Cells with Sigma Adjuvant in Each of 10 mice 1 8 t Boost: 1.0x10 6 Purified Human T Cells with Sigma Adjuvant in Each of 10 Mice 2nd Boost: 1.5x10 6 Purified T Cells with Sigma Adjuvant; 5 of the Mice with Human T Cells, the other 5 Mice with Cynomoigus T-Cells 3rd Boost: 50 ug Denatured Cyno CD3 Protein Mixed with 7 ug N-terminal Peptide-BSA (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT omit o His u Elio° im mom oimIE (10) International Publication Number WO 2018/208864 Al Figure 1 C (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/28 A61K 39/395 (2006.01) C07K 16/30 C07K 16/18 (2006.01) C07K 16/32 (21) International Application Number: PCT/US2018/031705 (22) International Filing Date: 08 May 2018 (08.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/503,315 08 May 2017 (08.05.2017) US (71) Applicant: ADIMAB, LLC [US/US]; 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (72) Inventors: WALKER, Laura M.; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). PEJCHAL, Robert; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). KRAULAND, Er- ic; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hamp- shire 03766 (US). VASQUEZ, Maximiliano; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). LEUNG, Monica Wai Ling; c/o Celgene Corpora- tion, 86 Morris Avenue, Summit, New Jersey 07901 (US). (74) Agent: SAHR, Robert N. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (2006.01) (2006.01) (2006.01) (54) Title: ANTI-CD3-BINDING DOMAINS AND ANTIBODIES COMPRISING THEM, AND METHODS FOR THEIR GENER- ATION AND USE 00 00 O (57) : Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desk- able T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their 0 identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, gen- \" crating and characterizing CD3 binding domains and antibodies comprising them are also provided. [Continued on next page] WO 2018/208864 Al MIDEDIMOMMIDIRE101001010MHOHNHIMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201910096R 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use SG11201910096RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762503315P 2017-05-08 2017-05-08
PCT/US2018/031705 WO2018208864A1 (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Publications (1)

Publication Number Publication Date
SG11201910096RA true SG11201910096RA (en) 2019-11-28

Family

ID=64104990

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201910096R SG11201910096RA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG10201912494TA SG10201912494TA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912494TA SG10201912494TA (en) 2017-05-08 2018-05-08 Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Country Status (11)

Country Link
US (2) US11542330B2 (en)
EP (1) EP3621641A4 (en)
JP (3) JP7393207B2 (en)
KR (1) KR20200053437A (en)
CN (1) CN110913895B (en)
AU (1) AU2018266711A1 (en)
BR (1) BR112019023111A2 (en)
CA (1) CA3062825A1 (en)
MX (1) MX2019013184A (en)
SG (2) SG11201910096RA (en)
WO (1) WO2018208864A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536247A (en) * 2019-06-07 2022-08-15 アディマブ・リミテッド・ライアビリティ・カンパニー High affinity anti-CD3 antibodies and methods of making and using the same
BR112021020426A2 (en) * 2019-06-07 2022-03-08 Adimab Llc Engineered pH-dependent anti-cd3 antibodies and methods for their generation and use
EP4031568A4 (en) * 2019-09-20 2023-09-20 Adimab, LLC Fc variants with reduced effector function
PE20221661A1 (en) * 2019-12-18 2022-10-26 Hoffmann La Roche BISPECIFIC ANTI-CCL2 ANTIBODIES
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
BR112022021780A2 (en) * 2020-04-27 2023-03-07 Twist Bioscience Corp CORONAVIRUS VARIANT NUCLEIC ACID LIBRARIES
CN111826400A (en) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 Preparation method of bispecific antibody NK cell, cell and application thereof
US20230374162A1 (en) * 2020-10-07 2023-11-23 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
CN114539415B (en) * 2020-11-24 2024-02-02 普米斯生物技术(珠海)有限公司 anti-PD-L1/VEGF/TGF-beta multi-specific antibody and application thereof
CN112578117B (en) * 2021-02-22 2021-05-25 信纳克(北京)生化标志物检测医学研究有限责任公司 Antibody composition and application thereof in screening post-transplantation lymphocyte proliferative diseases
CN112698044B (en) * 2021-03-23 2021-06-22 信纳克(北京)生化标志物检测医学研究有限责任公司 Device and method for evaluating immune state after targeted therapy
WO2023056556A1 (en) * 2021-10-07 2023-04-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
CN114573705A (en) * 2022-03-17 2022-06-03 杭州师范大学 Bispecific antibody for specifically starting anti-hepatitis B virus T cell immunity and application thereof
CN114605560B (en) * 2022-03-30 2024-02-20 江苏蒙彼利生物科技有限公司 CAR-NK cell and preparation method and application thereof
CN116925232A (en) * 2022-04-02 2023-10-24 普米斯生物技术(珠海)有限公司 Multispecific antibodies targeting CEACAM and CD3 and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
KR101266716B1 (en) * 2004-06-03 2013-05-31 노비뮨 에스 에이 Anti-cd3 antibodies and methods of use thereof
RU2012134369A (en) * 2010-01-11 2014-02-20 Алексион Фармасьютикалз, Инк BIOMARKERS OF IMMUNOMODULATING EFFECTS IN PEOPLE EXPOSED TO ANTIMETAL TREATMENT AGAINST CD200
CN107903325B (en) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 Multispecific FAB fusion proteins and methods of use thereof
CN103974977A (en) 2011-09-26 2014-08-06 Jn生物科学有限责任公司 Hybrid constant regions
NZ631543A (en) * 2012-03-28 2017-03-31 Sanofi Sa Antibodies to bradykinin b1 receptor ligands
PL3083689T3 (en) * 2013-12-17 2020-10-19 Genentech, Inc. Anti-cd3 antibodies and methods of use
EP3091032A1 (en) 2015-05-08 2016-11-09 Miltenyi Biotec GmbH Humanized antibody or fragment thereof specific for cd3

Also Published As

Publication number Publication date
EP3621641A4 (en) 2021-03-03
CA3062825A1 (en) 2018-11-15
CN110913895A (en) 2020-03-24
JP7393207B2 (en) 2023-12-06
JP2024032937A (en) 2024-03-12
MX2019013184A (en) 2020-02-07
US20230151097A1 (en) 2023-05-18
CN110913895B (en) 2024-04-02
RU2019139334A (en) 2021-06-09
BR112019023111A2 (en) 2020-07-28
RU2019139334A3 (en) 2021-08-25
SG10201912494TA (en) 2020-02-27
JP2020518650A (en) 2020-06-25
US20200190189A1 (en) 2020-06-18
EP3621641A1 (en) 2020-03-18
US11542330B2 (en) 2023-01-03
JP2023014324A (en) 2023-01-26
AU2018266711A1 (en) 2019-11-28
WO2018208864A1 (en) 2018-11-15
KR20200053437A (en) 2020-05-18

Similar Documents

Publication Publication Date Title
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811405QA (en) Improved differentiation method
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201804710TA (en) Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201903340TA (en) Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
SG11201810466PA (en) Compositions and methods related to engineered fc constructs
SG11201407819UA (en) Improved methods of cell culture for adoptive cell therapy
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201808314QA (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201909728XA (en) Constructs specifically recognizing glypican 3 and uses thereof